Backs FY25 adjusted combined R&D, APR&D, SG&A expenses view $4.9B-$5B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex will not progress VX-993 into pivotal development
- Vertex Pharmaceuticals reports Q2 EPS $3.99, consensus $4.25
- Vertex options imply 6.0% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, August 04, 2025
- VRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?